by Tara Fernandez | Feb 20, 2020
Immunotherapies have been heralded as a revolutionary paradigm shift in how cancer is treated, thanks to the exceptional cancer-killing properties of checkpoint inhibitors and chimeric antigen receptor (CAR) T cells. Today, approved therapies Yescarta™ and Kymriah™,...
by Sara M. Nolte | Feb 14, 2020
We’ve spent a lot of time swooning over CAR T-cells and CRISPR here at Signals, but recently a potential up-and-coming leading lady in the gene and cancer therapy fields has caught our eye. Our interest was piqued by a recent press release from The Max Delbruck Center...
by Stacey Johnson | Dec 20, 2019
Are you a risk taker? Do you pride yourself on giving unique and intriguing gifts? Well if you haven’t yet heard of Two Blind Brothers, pay attention. Two Blind Brothers produces clothing to fund blindness research at Foundation Fighting Blindness (FFB). As far as...
by CCRM Australia | Oct 10, 2019
Dr. Chih Wei Teng is Chief Operating Officer for CCRM Australia and wrote this blog with colleagues Alex Barrington and Dr. Emma Gallaher. To subscribe to the CCRM Australia newsletter: Click here Regenerative medicine is a risky business. The decades-long development...
by Erika Siren | Sep 11, 2019
At first pass, the skin and the gut are not so different: both are lined with an outer layer of cells that serve as the first line of protection from biological, chemical and physical wear-and-tear. Accordingly, both the gut and skin are subject to tissue breakdown...
Comments